Aktiesnakken — Juni 2013
-
godt HexaBody er tidlig phase
-
De har jo også punget godt ud for både Ibrutinib og Daratumumab
-
The deal includes Aragons and
rogen receptor antagonist program, which
includes the companys lead product candidate--known as ARN-509--for prostate
cancer. The treatment is in Phase 2 development. Aragons other assets will be
spun off into a new company in which J&J wont have an ownership stake. -
ja GSK har også været aktive
-
aftale
-
Vi mangler vel stadig DAHANCA data read out her i 2013 ?
-
ja hvor er den henne?
-
Jeg snakker med Rachel imorgen om alt fra A-Z og så laver jeg resume
Og det inkluderer også Zalu og Hexa -
please. Start i alfabetisk rækkefølge
-
og lad os håbe hun løber tør for tid
-
jeg får en dårlig
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind